Turn Biotechnologies Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
16
- Latest Deal Type
-
M&A
Turn Biotechnologies General Information
Description
Developer of longevity drugs designed to reverse aging and age-related diseases. The company's drugs induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue, enabling doctors to reprogram cells and combat disease.
Contact Information
Website
www.turn.bioCorporate Office
- 319 North Bernardo Avenue
- Mountain View, CA 94043
- United States
Corporate Office
- 319 North Bernardo Avenue
- Mountain View, CA 94043
- United States
Turn Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 21-May-2026 | Completed | Pre-Clinical Trials | |||
| 1. Later Stage VC (Series A) | 10-May-2024 | Completed | Pre-Clinical Trials |
Turn Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 6,172,838 | $0.000010 | 6% | $0.73 | $0.73 | 1x | $0.73 | 8.97% |
| Series A | 40,952,361 | $0.000010 | 6% | $0.86 | $0.86 | 1x | $0.86 | 34.56% |
Turn Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Turn Biotechnologies Patents
Turn Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026072801-A2 | Arrdc1-mediated microvesicle-based treatment of age-related macular degeneration | Pending | 26-Sep-2024 | ||
| WO-2026072801-A3 | Arrdc1-mediated microvesicle-based treatment of age-related macular degeneration | Pending | 26-Sep-2024 | ||
| AU-2024234052-A1 | Arrdc1-mediated microvesicle-based delivery of rna-guided proteins | Pending | 13-Mar-2023 | ||
| EP-4680617-A1 | Arrdc1-mediated microvesicle-based delivery of rna-guided proteins | Inactive | 13-Mar-2023 | ||
| EP-4638461-A1 | Dual lipid structures | Pending | 23-Dec-2022 | C07F9/091 |
Turn Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Turn Biotechnologies Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advani Family Office | Family Office | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Dhuna Ventures | Venture Capital | Minority | ||
| Formic Ventures | Venture Capital | Minority | ||
| Hanall Biopharma | Corporation | Minority |
Turn Biotechnologies Acquisitions (1)
Turn Biotechnologies’s most recent deal was a Merger/Acquisition with Vesigen Therapeutics. The deal was made on 26-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vesigen Therapeutics | 26-Mar-2025 | Merger/Acquisition | Drug Delivery |
Turn Biotechnologies Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Turn Biotechnologies (Epigenetic Reprogramming of Age Platform and eTurna RNA Delivery System) | Mountain View, CA |
Turn Biotechnologies FAQs
-
When was Turn Biotechnologies founded?
Turn Biotechnologies was founded in 2018.
-
Where is Turn Biotechnologies headquartered?
Turn Biotechnologies is headquartered in Mountain View, CA.
-
What is the size of Turn Biotechnologies?
Turn Biotechnologies has 16 total employees.
-
What industry is Turn Biotechnologies in?
Turn Biotechnologies’s primary industry is Drug Discovery.
-
Is Turn Biotechnologies a private or public company?
Turn Biotechnologies is a Private company.
-
What is Turn Biotechnologies’s current revenue?
The current revenue for Turn Biotechnologies is .
-
How much funding has Turn Biotechnologies raised over time?
Turn Biotechnologies has raised $29.1M.
-
Who are Turn Biotechnologies’s investors?
Advani Family Office, Astellas Venture Management, Dhuna Ventures, Formic Ventures, and Hanall Biopharma are 5 of 17 investors who have invested in Turn Biotechnologies.
-
When was Turn Biotechnologies acquired?
Turn Biotechnologies was acquired on 21-May-2026.
-
Who acquired Turn Biotechnologies?
Turn Biotechnologies was acquired by Daewoong Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
